Drug Profile


Alternative Names: 1325756; GSK-1325756; GSK-1325756H; GSK1325756B

Latest Information Update: 16 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlaxoSmithKline
  • Class Anti-inflammatories; Antivirals; Piperidines; Sulfones
  • Mechanism of Action Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease; Influenza virus infections

Most Recent Events

  • 18 May 2017 GlaxoSmithKline plans a pilot phase II trial for Chronic obstructive pulmonary disease in USA (NCT03170232)
  • 10 May 2017 Phase-I clinical trials in Chronic obstructive pulmonary disease (In the elderly, In volunteers) in Japan (PO) (NCT03136380)
  • 05 May 2017 GlaxoSmithKline plans a phase I trial for Chronic obstructive pulmonary disease (In volunteers, In the elderly) in Japan (NCT03136380)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top